Literature DB >> 759070

Mechanisms of nonlinear disposition kinetics of sulfamethazine.

P du Souich, D Lalka, R Slaughter, A T Elvin, A J McLean.   

Abstract

Five healthy male subjects received oral doses of 10 and 40 mg/kg of sulfamethazine (SMZ) approximately 14 days apart in a nonrandomized crossover study. Blood and urine samples were collected for at least 24 and 72 hr, respectively. All samples were assayed by the Bratton-Marshall procedure for SMZ and apparent N-acetylsulfamethazine (NSMZ). Recovery of total drug (SMZ + NSMZ) in urine was 88.9% following the low and 79.5% following the high dose. The low and high dose plasma concentration time curves were not readily superimposable (i.e., nonlinear kinetic behavior was observed). The data suggest that several mechanisms contribute to the nonlinearity. Specifically, a dose-dependent decrease in absorption rate displaced the plasma concentration-time curve to the right in some subjects, whereas apparent metabolic clearance (Clm) decreased with increasing dose (estimated assuming dose = amount of SMZ + NSMZ in urine to 72 hr) in all subjects (0.35 ml/min/kg for the low and 0.23 for the high dose). Still greater dose-dependent effects were found when apparent Clm of unbound drug was determined, since free fraction rose from 0.11 to 0.30 over the observed plasma concentration range. Renal clearance (ClR) of Smz appeared to be a complex function of time. In the low dose study it ranged from an average of 0.071 ml/min/kg at 2 hr to 0.146 ml/min/kg at 6 hr after drug. After the high dose comparable values were 0.083 and 0.128. Interindividual variability and pronounced nonlinear kinetics of SMZ after 40 mg/kg suggest that this dose is probably a poor choice for the determination of acetylator phenotype.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 759070     DOI: 10.1002/cpt1979252172

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

2.  Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine.

Authors:  T Zysset; E Peretti
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

Review 4.  Dose-dependent pharmacokinetics and cancer chemotherapy.

Authors:  G Powis; M M Ames; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Effects of concurrent administration of other substrates of N-acetyltransferase on dapsone acetylation.

Authors:  R A Ahmad; H J Rogers; M Vandenburg; P Wright
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

6.  Displacement of lidocaine from serum alpha 1-acid glycoprotein binding sites by basic drugs.

Authors:  D L Goolkasian; R L Slaughter; D J Edwards; D Lalka
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  High performance liquid chromatographic characterisation and quantitation of p-aminobenzoic acid N-acetylation in Chinese subjects.

Authors:  K Chan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

Review 8.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.